Shaperon logo. /Rangfun Media Drug development company Shaperon is entering the aesthetic device market with a 3.7 billion won investment as part of its business diversification efforts. Shaperon said in a disclosure on the 11th that it had decided to acquire 60,000 shares, repre
2026-06-11
AI-generated image. /Rangfun Media Mike Doustdar, chief executive officer (CEO) of Novo Nordisk, expressed strong confidence in the company’s competition with Eli Lilly, buoyed by the successful launch of oral Wegovy, an obesity treatment. According to biopharmaceutical news outl
2026-06-11
AI-generated image. / Rangfun Media Kardigan, founded by key figures from MyoKardia, which was acquired by Bristol Myers Squibb (BMS) for 19 trillion won, plans to raise up to 530 billion won through a Nasdaq listing. According to foreign media outlets, including Fierce Biotech,
2026-06-11
Image for illustrative purposes / Generated by FLUX AI Waters has launched a new reversed-phase (RP) column platform designed to address the challenge of separating impurities in GLP-1 (glucagon-like peptide-1) agonists and lipid nanoparticle (LNP)-based drug development. Waters
2026-06-10
AI-generated image. / Rangfun Media The Korea Research Institute of Chemical Technology has launched a public service that can simultaneously screen tens of millions of drug candidates. According to Ajou Life Science and other life sciences media outlets on the 10th, the Korea Re
2026-06-10
Image for illustrative purposes / Generated by FLUX AI Waters Corporation has launched a new reversed-phase (RP) column platform designed to address bottlenecks in the development of GLP-1 and lipid nanoparticle (LNP) drugs. Waters said on the 10th (local time) that it unveiled t
2026-06-10
Image for illustrative purposes / Generated by FLUX AI U.K.-based pharmaceutical company GSK is strengthening its oncology pipeline by acquiring a U.S. biotech for more than 15 trillion won. GSK announced that it will acquire U.S. biotech company Nuvalent for $11 billion (approxi
2026-06-10
Image for illustrative purposes / Generated by FLUX AI A new biotech company founded by an oncology drug development expert who previously scored an $11 billion “jackpot” has announced plans to enter the Nasdaq through a reverse merger. According to the biotech publication BioPha
2026-06-10
Image for illustrative purposes / Generated by FLUX AI Hanmi Pharmaceutical has licensed to Eli Lilly and Co. a drug candidate it is developing as a treatment for short bowel syndrome (SBS). According to Nikkei Biotechnology Online in Japan on the 10th, Hanmi Pharmaceutical annou
2026-06-10
AI-generated image. / Rangfun Media KOSDAQ drug developers Curian and Voronoi are trading at valuations exceeding 30 times their net assets. The two companies’ price-to-book ratios (PBRs) are 33.81 and 38.29, respectively. A metric typically considered normal at around 1 exceedin
2026-06-10
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
